Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Athira Pharma's share price for the quarter that ended in Dec. 2023 was $2.43. Athira Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 38.17 Mil. Therefore, Athira Pharma's market cap for the quarter that ended in Dec. 2023 was $92.76 Mil.
Athira Pharma's quarterly market cap
declined
from Jun. 2023 ($112.26 Mil) to Sep. 2023 ($76.87 Mil) but then
increased
from Sep. 2023 ($76.87 Mil) to Dec. 2023 ($92.76 Mil).
Athira Pharma's annual market cap
declined
from Dec. 2021 ($487.05 Mil) to Dec. 2022 ($120.07 Mil) and
declined
from Dec. 2022 ($120.07 Mil) to Dec. 2023 ($92.76 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Athira Pharma's Enterprise Value for Today is $-71.10 Mil.
Athira Pharma Market Cap Historical Data
The historical data trend for Athira Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Athira Pharma's Market Cap
For the Biotechnology subindustry, Athira Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Athira Pharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Athira Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Athira Pharma's Market Cap falls into.
Athira Pharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Athira Pharma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athira Pharma (NAS:ATHA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Athira Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of Athira Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Athira Pharma (Athira Pharma) Business Description
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATHA has been successfully added to your 